PMID- 35402293 OWN - NLM STAT- MEDLINE DCOM- 20220412 LR - 20221207 IS - 2235-2988 (Electronic) IS - 2235-2988 (Linking) VI - 12 DP - 2022 TI - Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients. PG - 820367 LID - 10.3389/fcimb.2022.820367 [doi] LID - 820367 AB - BACKGROUND: Increasing evidence shows that alterations in gut microbiome (GM) contribute to the development of type 2 diabetes mellitus (T2DM), and fecal microbiota transplantation (FMT) successfully treats various human diseases. However, the benefits of FMT therapy to T2DM patients remain unknown. METHODS: We enrolled 17 patients with T2DM for nonblinded, one-armed intervention trial of FMT. A total of 20 healthy individuals were recruited as the baseline control. HbA1c% and metabolic parameter change were evaluated in 17 T2DM patients 12 weeks after they received FMT from healthy donors. The GM composition was characterized by 16S rRNA gene amplicon sequencing from fecal samples prior to and 12 weeks after FMT treatment. RESULTS: We found that the GM of T2DM patients was reconstituted by FMT. We observed a statistically significant decrease in HbA1c% (from 7.565 +/- 0.148 to 7.190 +/- 0.210, p<0.01), blood glucose (from 8.483 +/- 0.497 to 7.286 +/- 0.454 mmol/L, p<0.01), and uric acid (from 309.4 +/- 21.5 to 259.1 +/- 15.8 micromol/L, p<0.01) while a significant increase in postprandial C-peptide (from 4.503 +/- 0.600 to 5.471 +/- 0.728 ng/ml, p<0.01) at 12 weeks after FMT. Closely evaluating the changes in these assays, we found individual variability in response to FMT treatment. Out of 17 T2DM patients, 11 were found to significantly improve T2DM symptoms. The FMT responders have significantly higher levels of the family Rikenellaceae and the genus Anaerotruncus (family Ruminococcaceae) in their pretreated fecal in comparison to nonresponders, which could predict the clinical response with an area under the curve of 0.83. CONCLUSION: Our findings suggest that certain T2DM patients can potentially benefit from FMT, and the pretreated abundance of Rikenellaceae and Anaerotruncus in the fecal of patients may serve as potential biomarkers for selecting T2DM patients to receive FMT. CI - Copyright (c) 2022 Ding, Yong, You, Lu, Yang, Ye, Wang, Cai, Zheng, Chen, Cui, Zhang, Liu, Mao, Lu and Chang. FAU - Ding, Dafa AU - Ding D AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yong, Huijuan AU - Yong H AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - You, Na AU - You N AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Lu, Wei AU - Lu W AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Yang, Xu AU - Yang X AD - Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China. AD - Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. AD - Biomedical Data Science Center, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. FAU - Ye, Xiaolong AU - Ye X AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wang, Yayun AU - Wang Y AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cai, Tingting AU - Cai T AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zheng, Xiaoling AU - Zheng X AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Chen, Hui AU - Chen H AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Cui, Bota AU - Cui B AD - Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zhang, Faming AU - Zhang F AD - Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Liu, Xingyin AU - Liu X AD - Department of Pathogen Biology-Microbiology Division, Key Laboratory of Pathogen of Jiangsu Province, Nanjing Medical University, Nanjing, China. FAU - Mao, Jian-Hua AU - Mao JH AD - Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. AD - Biomedical Data Science Center, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. FAU - Lu, Yibing AU - Lu Y AD - Department of Endocrinology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Chang, Hang AU - Chang H AD - Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. AD - Biomedical Data Science Center, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220325 PL - Switzerland TA - Front Cell Infect Microbiol JT - Frontiers in cellular and infection microbiology JID - 101585359 RN - 0 (Glycated Hemoglobin A) RN - 0 (RNA, Ribosomal, 16S) SB - IM MH - *Diabetes Mellitus, Type 2/therapy MH - *Fecal Microbiota Transplantation MH - Feces MH - Glycated Hemoglobin MH - Humans MH - Prospective Studies MH - RNA, Ribosomal, 16S/genetics MH - Treatment Outcome PMC - PMC8990819 OTO - NOTNLM OT - fecal microbiota transplantation OT - gut microbiome OT - prospective cohort study OT - therapeutic biomarker OT - type 2 diabetes mellitus COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/04/12 06:00 MHDA- 2022/04/13 06:00 PMCR- 2022/01/01 CRDT- 2022/04/11 05:31 PHST- 2021/12/01 00:00 [received] PHST- 2022/02/23 00:00 [accepted] PHST- 2022/04/11 05:31 [entrez] PHST- 2022/04/12 06:00 [pubmed] PHST- 2022/04/13 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcimb.2022.820367 [doi] PST - epublish SO - Front Cell Infect Microbiol. 2022 Mar 25;12:820367. doi: 10.3389/fcimb.2022.820367. eCollection 2022.